Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on BiomX. The associated price target remains the same with $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including the temporary nature of the clinical hold on BiomX’s BX004 Phase 2 trial, which is unrelated to the drug itself but rather to a third-party nebulizer device. The company has already submitted the necessary safety data to the FDA, and Pantginis anticipates a swift resolution with minimal impact on clinical timelines.
Furthermore, BiomX’s financial position appears stable with sufficient cash to fund operations through the first quarter of 2026. The company is actively advancing its lead assets, BX211 and BX004, with promising developments such as positive topline results from the Phase 2 trial of BX211. These factors, combined with upcoming catalysts and ongoing regulatory discussions, contribute to Pantginis’s optimistic outlook and Buy rating for BiomX.